Alnylam Pharmaceuticals Inc (ALNY)
246.80
-1.99
(-0.80%)
USD |
NASDAQ |
Nov 21, 16:00
249.68
+2.88
(+1.17%)
After-Hours: 20:00
Alnylam Pharmaceuticals Gross Profit Margin (Quarterly): 82.85% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 82.85% |
| June 30, 2024 | 89.59% |
| March 31, 2024 | 86.65% |
| December 31, 2023 | 80.47% |
| September 30, 2023 | 88.77% |
| June 30, 2023 | 73.22% |
| March 31, 2023 | 82.82% |
| December 31, 2022 | 84.70% |
| September 30, 2022 | 84.44% |
| June 30, 2022 | 81.85% |
| March 31, 2022 | 83.29% |
| December 31, 2021 | 85.43% |
| September 30, 2021 | 82.59% |
| Date | Value |
|---|---|
| June 30, 2021 | 82.43% |
| March 31, 2021 | 82.51% |
| December 31, 2020 | 85.92% |
| September 30, 2020 | 82.68% |
| June 30, 2020 | 80.83% |
| March 31, 2020 | 86.63% |
| December 31, 2019 | 83.01% |
| September 30, 2019 | 92.56% |
| June 30, 2019 | 90.33% |
| March 31, 2019 | 89.95% |
| December 31, 2018 | 92.08% |
| September 30, 2018 | 93.38% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
73.22%
Minimum
Jun 2023
89.59%
Maximum
Jun 2024
83.53%
Average
82.93%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Pfizer Inc | 70.27% |
| BridgeBio Pharma Inc | 78.11% |
| Gilead Sciences Inc | 79.14% |
| Johnson & Johnson | 69.01% |
| Regeneron Pharmaceuticals Inc | 86.80% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -8.43% |
| Return on Invested Capital | -36.66% |
| Profit Margin (Quarterly) | -22.27% |
| Operating Margin (Quarterly) | -15.35% |
| Return on Net Operating Assets | -29.30% |